Can we safely reduce the administration of 131-iodine in patients with differentiated thyroid cancer? – experience of the Brugmann hospital in Brussels

BACKGROUND: 131-iodine ((131)I) administration after surgery remains a standard practice in differentiated thyroid cancer (DTC). In 2014, the American Thyroid Association presented new guidelines for the staging and management of DTC, including no systematic (131)I in patients at low-risk of recurre...

Descripción completa

Detalles Bibliográficos
Autores principales: Iconaru, Laura, Baleanu, Felicia, Taujan, Georgiana, Duttmann, Ruth, Spinato, Linda, Karmali, Rafik, Bergmann, Pierre, Hambye, Anne-Sophie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488699/
https://www.ncbi.nlm.nih.gov/pubmed/32944083
http://dx.doi.org/10.1186/s13044-020-00089-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7488699/
https://www.ncbi.nlm.nih.gov/pubmed/32944083
http://dx.doi.org/10.1186/s13044-020-00089-4

Ejemplares similares